Literature DB >> 18342786

Incidence, predisposing factors, and outcome of engraftment syndrome in pediatric allogeneic stem cell transplant recipients.

Irene Schmid1, Daniel Stachel, Philipp Pagel, Michael H Albert.   

Abstract

Engraftment syndrome (ES) has been recognized as an inflammatory condition during neutrophil recovery after hematopoietic stem cell transplantation (HSCT) characterized by noninfectious fever and skin rash. It has been reported to occur frequently after autologous HSCT in children and adults, and has been shown to be an independent risk factor for increased transplant-related mortality (TRM). However, virtually no data exist on its occurrence after allogeneic HSCT in children. To determine incidence, predisposing factors for, and complications of ES in a pediatric transplant cohort, we analyzed 61 consecutive recipients of a myeloablative allogeneic HSCT for the occurrence of ES. Diagnosis of ES was established when children presented with > or =2 of the following symptoms within 7 days before engraftment: (1) fever >38.0 degrees C, (2) skin rash, (3) weight gain and albumin drop, or (4) dyspnea, hypoxia, and pulmonary infiltrates. Incidence of ES in this cohort was 48% (29 of 61). In a univariate analysis, posttransplant granulocyte-colony stimulating factor (G-CSF) administration (P = .02), and high mononuclear cell count (MNC) (P = .002) were identified as significant risk factors predisposing for the development of ES. In a multiple logistic regression analysis, amphotericin B therapy (P = .009) and high MNC (P = .004) were significant explanatory variables for ES risk. There was a slight trend toward a higher rate of chronic GVHD (cGVHD) in patients with ES (P = .11). However, after a median follow-up of 9.5 years overall survival (OS) (P = .53) and TRM (P = .65) did not differ between the 2 groups. ES presenting with fever, rash, weight gain, and pulmonary symptoms should be recognized as a frequent complication of allogeneic HSCT after myeloablative conditioning in children. Treatment with G-CSF, amphotericin B, and a high nucleated cell count of the graft predisposed for the development of ES in this study. OS and TRM in this cohort were not affected by the occurrence of ES.

Entities:  

Mesh:

Year:  2008        PMID: 18342786     DOI: 10.1016/j.bbmt.2008.02.002

Source DB:  PubMed          Journal:  Biol Blood Marrow Transplant        ISSN: 1083-8791            Impact factor:   5.742


  10 in total

1.  Engraftment Syndrome and Acute Graft-versus-Host Disease: A Meta-Analysis.

Authors:  Kittika Poonsombudlert; Jakrin Kewcharoen; Chattip Prueksapraopong; Nath Limpruttidham
Journal:  Hawaii J Health Soc Welf       Date:  2020-06-01

Review 2.  Engraftment syndrome: double-edged sword of hematopoietic cell transplants.

Authors:  T R Spitzer
Journal:  Bone Marrow Transplant       Date:  2015-01-12       Impact factor: 5.483

3.  Prognostic factors and outcomes for pediatric patients receiving an haploidentical relative allogeneic transplant using CD3/CD19-depleted grafts.

Authors:  M A Diaz; A Pérez-Martínez; B Herrero; N Deltoro; I Martinez; M Ramirez; L Abad; J Sevilla; E Merino; J Ruiz; J L Vicario; M Gonzalez-Vicent
Journal:  Bone Marrow Transplant       Date:  2016-04-18       Impact factor: 5.483

4.  Pre-engraftment syndrome after double-unit cord blood transplantation: a distinct syndrome not associated with acute graft-versus-host disease.

Authors:  Kevin J Patel; Robert D Rice; Rebecca Hawke; Michelle Abboud; Glenn Heller; Andromachi Scaradavou; James W Young; Juliet N Barker
Journal:  Biol Blood Marrow Transplant       Date:  2009-10-24       Impact factor: 5.742

5.  Engraftment syndrome after allogeneic hematopoietic cell transplantation predicts poor outcomes.

Authors:  Lawrence Chang; David Frame; Thomas Braun; Erin Gatza; David A Hanauer; Shuang Zhao; John M Magenau; Kathryn Schultz; Hemasri Tokala; James L M Ferrara; John E Levine; Pavan Reddy; Sophie Paczesny; Sung Won Choi
Journal:  Biol Blood Marrow Transplant       Date:  2014-06-02       Impact factor: 5.742

6.  Pulmonary manifestations of the pre-engraftment syndrome after umbilical cord blood transplantation.

Authors:  Kyle R Brownback; Steven Q Simpson; Joseph P McGuirk; Tara L Lin; Sunil Abhyankar; Siddhartha Ganguly; Omar S Aljitawi
Journal:  Ann Hematol       Date:  2013-12-18       Impact factor: 3.673

7.  Dexamethasone palmitate for patients with engraftment syndrome is associated with favorable outcome for children with hematological malignancy.

Authors:  H Sakaguchi; K Matsumoto; N Yoshida; K Narita; M Hamada; S Kataoka; N Miyagawa; T Yoshikawa; M Ito; K Kato
Journal:  Bone Marrow Transplant       Date:  2016-07-04       Impact factor: 5.483

8.  Comparison of procalcitonin and C-reactive protein as early diagnostic marker for the identification of transplant-related adverse events after allogeneic hematopoietic stem cell transplantation in pediatric patients.

Authors:  Karin Melanie Cabanillas Stanchi; Manon Queudeville; Carmen Malaval; Judith Feucht; Patrick Schlegel; Markus Dobratz; Christian Seitz; Ingo Müller; Peter Lang; Rupert Handgretinger; Michaela Döring
Journal:  J Cancer Res Clin Oncol       Date:  2019-08-24       Impact factor: 4.322

Review 9.  Early Onset Noninfectious Pulmonary Syndromes after Hematopoietic Cell Transplantation.

Authors:  Lisa K Vande Vusse; David K Madtes
Journal:  Clin Chest Med       Date:  2017-06       Impact factor: 2.878

10.  Appropriate dose reduction in induction therapy is essential for the treatment of infants with acute myeloid leukemia: a report from the Japanese Pediatric Leukemia/Lymphoma Study Group.

Authors:  Daisuke Tomizawa; Akio Tawa; Tomoyuki Watanabe; Akiko Moriya Saito; Kazuko Kudo; Takashi Taga; Shotaro Iwamoto; Akira Shimada; Kiminori Terui; Hiroshi Moritake; Akitoshi Kinoshita; Hiroyuki Takahashi; Hideki Nakayama; Nobutaka Kiyokawa; Keiichi Isoyama; Shuki Mizutani; Junichi Hara; Keizo Horibe; Tatsutoshi Nakahata; Souichi Adachi
Journal:  Int J Hematol       Date:  2013-09-26       Impact factor: 2.490

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.